Price Predictions - End of Year, page-9

1. Do you really think once this goes into a FDA trial no US money is coming to the ASX . AVR has no intention of getting full approval for the TAVR , WP has already stated he’s had talks with both the major players here . Medtronic’s paid $800 million for Corevales unapproved inferior valve 13 years ago and at that time the TAVR market would have been less than 5 billion . Do you honestly believe that AVR would only be worth $720 million with the TAVR and the ADAPT all approved ? If AVR was to take the TAVR all the way to approval it would be a multi billion dollar company and probably would be looking at partnering with one of the majors not selling . IMO a lot of people are not taking into account the market here and don’t realise how AVRs TAVR has the potential to dominate this market